Following the temporary stop by the Ministry of Health (MHLW) of 11 medical institutions which had used umbelical cord stem cells obtained from third parties for the treatment of patients without going through formal registration and evaluation according to the new Pharmaceutical and Medical Devices Act passed in 2014 the JSRM considers to exclude members who have been involved in such fraud.

Nikkei Biotech news release, July 5, 2017